Payment overview · 2025
General Payments
$552.00
26 reported records · 12 companies
Healthcare provider profile · identity verified
David Arnold Montgomery, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HENDERSONVILLE, TN · NPI 1932462959
Verified facts
What the public records show
CMS Open Payments records show David Arnold Montgomery, M.D. received $552.00 in general payments during 2025 across 26 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 237 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $112.38 | 20.4% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $88.95 | 16.1% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.01 | 12.1% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $56.06 | 10.2% | 3 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $51.04 | 9.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $37.28 | 6.8% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.76 | 5.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $23.38 | 4.2% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $22.12 | 4.0% | 1 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $21.98 | 4.0% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.47 | 3.9% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $20.57 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.00 | 26 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.01 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $66.76 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $56.06 | 3 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $42.36 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.76 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $28.83 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $23.38 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| WaveWriter Alpha Prime 16 Normalized: wavewriter alpha prime 16 |
Device | Boston Scientific Corporation | $22.21 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $22.12 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $21.98 | 1 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.47 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $20.57 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $20.45 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 121 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 237 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 52 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
52 | 16 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
121 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
237 | 50 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1103 | 263 |
| Levothyroxine Sodium | Levothyroxine Sodium | 648 | 140 |
| Amlodipine Besylate | Amlodipine Besylate | 567 | 148 |
| Omeprazole | Omeprazole | 481 | 113 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 454 | 126 |
| Losartan Potassium | Losartan Potassium | 451 | 129 |
| Furosemide | Furosemide | 431 | 49 |
| Eliquis | Apixaban | 429 | 32 |
| Lisinopril | Lisinopril | 390 | 110 |
| Metformin Hcl Er | Metformin Hcl | 356 | 104 |
| Simvastatin | Simvastatin | 323 | 76 |
| Metoprolol Tartrate | Metoprolol Tartrate | 319 | 63 |
| Potassium Chloride | Potassium Chloride | 301 | 66 |
| Carvedilol | Carvedilol | 260 | 55 |
| Sertraline Hcl | Sertraline Hcl | 247 | 53 |
| Ozempic | Semaglutide | 237 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 233 | 59 |
| Allopurinol | Allopurinol | 231 | 44 |
| Escitalopram Oxalate | Escitalopram Oxalate | 222 | 32 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 71 |
| Tamsulosin Hcl | Tamsulosin Hcl | 204 | 56 |
| Gabapentin | Gabapentin | 187 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 32 |
| Duloxetine Hcl | Duloxetine Hcl | 165 | 29 |
| Metformin Hcl | Metformin Hcl | 162 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 158 | 53 |
| Trazodone Hcl | Trazodone Hcl | 156 | 55 |
| Alendronate Sodium | Alendronate Sodium | 140 | 49 |
| Buspirone Hcl | Buspirone Hcl | 139 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 139 | 16 |
| Finasteride | Finasteride | 129 | 23 |
| Montelukast Sodium | Montelukast Sodium | 122 | 29 |
| Jardiance | Empagliflozin | 121 | 31 |
| Donepezil Hcl | Donepezil Hcl | 120 | suppressed |
| Bupropion Xl | Bupropion Hcl | 117 | 38 |
| Xarelto | Rivaroxaban | 115 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 111 | 26 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 107 | 32 |
| Ezetimibe | Ezetimibe | 103 | 32 |
| Mirtazapine | Mirtazapine | 102 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 16 |
| Levetiracetam | Levetiracetam | 89 | suppressed |
| Myrbetriq | Mirabegron | 88 | suppressed |
| Clonazepam | Clonazepam | 86 | 18 |
| Alprazolam | Alprazolam | 84 | 19 |
| Famotidine | Famotidine | 79 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 78 | 14 |
| Tramadol Hcl | Tramadol Hcl | 78 | 23 |
| Baclofen | Baclofen | 77 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 77 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 74 | 14 |
| Spironolactone | Spironolactone | 73 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 72 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 68 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 66 | 23 |
| Glipizide | Glipizide | 65 | 23 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 64 | 17 |
| Trulicity | Dulaglutide | 64 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 59 | 45 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 17 |
| Prednisone | Prednisone | 56 | 41 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 55 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 54 | 19 |
| Nifedipine Er | Nifedipine | 54 | 12 |
| Atenolol | Atenolol | 52 | 16 |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Meloxicam | Meloxicam | 52 | 19 |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Mounjaro | Tirzepatide | 48 | suppressed |
| Estradiol | Estradiol | 47 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 44 |
| Namzaric | Memantine Hcl/Donepezil Hcl | 45 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | 12 |
| Cephalexin | Cephalexin | 44 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 42 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 26 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Lovastatin | Lovastatin | 41 | suppressed |
| Olanzapine | Olanzapine | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 11 |
| Celecoxib | Celecoxib | 38 | suppressed |
| Temazepam | Temazepam | 38 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 37 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 37 | suppressed |
| Latanoprost | Latanoprost | 37 | suppressed |
| Glimepiride | Glimepiride | 35 | 12 |
| Diazepam | Diazepam | 34 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 33 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 32 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 11 |
| Methylprednisolone | Methylprednisolone | 31 | 27 |
| Azelastine Hcl | Azelastine Hcl | 30 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 30 | 18 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 29 | 29 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 29 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 28 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 20 |
| Linzess | Linaclotide | 26 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 26 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 23 | 13 |
| Fenofibrate | Fenofibrate | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | 11 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 22 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | suppressed |
| Nyamyc | Nystatin | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Repatha Sureclick | Evolocumab | 21 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 21 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 20 | suppressed |
| Bumetanide | Bumetanide | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Bethanechol Chloride | Bethanechol Chloride | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 15 |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 17 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 17 | suppressed |
| Acyclovir | Acyclovir | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Torsemide | Torsemide | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Nateglinide | Nateglinide | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Calcitriol | Calcitriol | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 14 | suppressed |
| Ondansetron Odt | Ondansetron | 14 | suppressed |
| Fluconazole | Fluconazole | 13 | 12 |
| Folic Acid | Folic Acid | 13 | suppressed |
| Gemfibrozil | Gemfibrozil | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 13 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Premarin | Estrogens, Conjugated | 13 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 12 | suppressed |
| Humulin R | Insulin Regular, Human | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Prozac | Fluoxetine Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.00 · 26 records | Novo Nordisk Inc | AURYON LASER SYSTEM 100-120 VAC, AUSTEDO XR, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, JARDIANCE, Kerendia, Korlym, LEQVIO, Ozempic, REXULTI, SYNTHROID, The Cologuard Plus Collection Kit, UBRELVY, VIBERZI, WATCHMAN Access System, WaveWriter Alpha Prime 16, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error